Plasma cell myeloma accounts for 1% of malignant tumors and 10%-15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA, which is a CD38-targeted immunomodulatory drug, also cross-reacts with red cells and sensitizes them, causing difficulties and delay in the blood bank. To avoid delay in view of patient care, proper communication with blood bank professionals is required. We present a case of relapsed/refractory multiple myeloma in a 45-year-old male who required transfusions due to anemia and severe thrombocytopenia.
Introduction
T ransfusion medicine has evolved in recent years, but the principle of red cell serology is still simple and same, namely the antigen-antibody interaction.
Plasma cell myeloma accounts for 1% of malignant tumors and 10%-15% of hematopoietic neoplasms. [1] Daratumumab (DARA), a new novel targeted immunotherapy drug, was approved by the Food and Drug Administration (FDA) to treat relapsed/refractory multiple myeloma. DARA works by targeting the CD38 portion of malignant plasma cells; however, this drug cross-reacts and binds to endogenous CD38 on red blood cells (RBCs) and attaches to red cell reagents used for antibody screening in blood banks causing serological interference like pan positivity in antibody screening, positive DAT, and incompatibility during crossmatch. [2] [3] [4] However, it does not interfere with ABO grouping and Rh typing.
Here, we describe the interference of DARA in the red cell compatibility testing of a patient with refractory multiple myeloma.
2. The donor units were compatible in immediate spin crossmatch 3. Clinical history revealed two doses of DARA being received by the patient.
Even though dithiothreitol (DTT)-based pretransfusion testing can be used to negate the drug interference, we suspected that DARA interfered in compatibility testing with the test findings and clinical history. The patient was transfused with two units of B-positive red cell unit, and no transfusion reaction was observed.
Discussion
Multiple myeloma is a diverse clonal plasma cell malignancy that results from complex interactions between malignant progenitor cells (mature B lymphocytes), bone marrow stromal cells, and the bone marrow microenvironment. [5] Primary refractory disease means that the patient has failed to achieve any response to initial multiple myeloma treatments, often a combination regimen of two or three novel agents. [3, 6] DARA, a new novel targeted immunotherapy therapy drug, was approved by the FDA in March 2015. It is the first-class anti-CD38 monoclonal antibody, [7, 8] which produces antibodies toward CD38 on the proliferating plasma cells. In addition to being expressed by leukocytes, CD38 is also seen on erythrocytes, platelets, and immature cells of the bone marrow, and CD38 is also expressed by neuronal cells and glial cells of the central nervous system, peripheral nerves, bronchial epithelium, osteoclasts, pancreatic islet cells, and skeletal and cardiac muscle cells. [9] Several trials were done to avoid serious damage to occur to the patients because of unwanted reactions with normal tissues. As CD38 expression is high in refractory myeloma cells, DARA was taken as treatment of choice.
Pan reactivity with reagent red cells and false-positive indirect ant globulin test (IAT) results in patients receiving DARA, which can last up to 5-6 months, is a huge concern in transfusion medicine. However, the drug does not affect the patients' ABO blood grouping and immediate spin crossmatch. It binds to endogenous CD38 on RBCs. Such sensitized RBCs agglutinate in the Coombs phase resulting in pan reactivity in vitro (antibody screening/identification and crossmatching). [10] It has been shown that dithiothreitol (DTT) treatment of RBC screening cells negated the interference by DARA. Several studies including one from India by Setia R et al., have described ways of overcoming Daratumumab resistance. [11] The limitations of our study was that it did not involve DTT treatment and perhaps more research is needed to standardize DTT cross match in such patients.
The researchers discovered that DTT treatment of RBC screening cells negated the interference by DARA. DTT is a reducing agent and acts by denaturing CD38 by cleaving the disulfide bonds; however, caution is necessary as some RBC antigens such as the Kell antigen can be destroyed by DTT. This problem can be solved by giving packed red cells which react negatively to the Kell antigen. A strong alternative in denaturing CD38 is 1% trypsin because it does not destroy the Kell antigen.
Delayed transfusions due to complications caused by DARA can pose a serious threat to patient safety. This threat can be avoided by informing the transfusion service whenever any patient is scheduled to begin taking anti-CD38. A baseline type and screen and if possible a baseline phenotype or genotype is advised for such patients. [12] Conclusion DARA is emerging as a good targeted immunotherapy drug in patients with primary refractory multiple myeloma but has certain limitations. Due to the presence of CD38 receptors on other cells in the body, cross-reactions occur and interfere with compatibility testing, leading to misinterpretations and delay in issuing blood for transfusion which affect patients' care.
Appropriate guidance from AABB, drug manufacturer supplemented with proper communication between health-care professionals, and the transfusion medicine department will ensure minimal adverse impact when dealing with DARA.
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